Personalized one-two punches for lung cancer

• 来源期刊: 细胞研究（英文版）
• 年，卷（期）: 2015,（3）
• 页码范围: 269-270
• 页数: 2页
• 语种: 中文
• DOI: 10.1038/cr.2014.168

摘要

Discovery of individualized therapies to address resistance to tyrosine kinase inhibitors (TKIs) has been hampered by the inability to test drug combinations on patient samples before and after TKI resistance.A recent study published in Science by Crystal et al.describes a methodology for pharmacological screening using a panel of 76 targeted agents and cell lines made directly from patient biopsies. Genetic characterization of tumors and the subsequent use of TKIs as targeted therapies has become a mainstream treatment modality for a subset of non-small cell lung cancer (NSCLC).